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doi:10.1Objective: Ischemia–reperfusion injury is among the most serious problems in cardiac surgery. Epigallocatechin-
3-gallate, a major polyphenolic component of green tea, is thought to be cardioprotective through its antioxidant
activities. We investigated cardioprotective effects of oral epigallocatechin-3-gallate pretreatment against ische-
mia–reperfusion injury in isolated rat hearts and considered possible underlying mechanisms.
Methods: Rats were given epigallocatechin-3-gallate solution orally at 0.1, 1, or 10 mmol/L (n ¼ 12 per group)
for 2 weeks; controls (n ¼ 12) received tap water alone for 2 weeks. Subsequently, Langendorff-perfused hearts
were subjected to global ischemia for 30 minutes, followed by 60 minutes of reperfusion.
Results: Recoveries at 60 minutes after reperfusion of left ventricular developed pressure and maximum positive
and minimum negative first derivatives of left ventricular pressure were significantly higher in 1-mmol/L group
than in 0.1-mmol/L (P< .0001), 10-mmol/L (P< .05), and control (P< .0001) groups. Oxidative stress after
reperfusion, as reflected by 8-hydroxy-20-deoxyguanosine index, was lower in 1-mmol/L group than in control
(P< .01) and 0.1-mmol/L (P< .05) groups. Western blot analysis after reperfusion showed p38 activation
and active caspase-3 expression to be lower in 1-mmol/L group than in control group (P< .05).
Conclusions: Oral pretreatment with epigallocatechin-3-gallate preserved cardiac function after ischemia–reper-
fusion, an effect that may involve its antioxidative, antiapoptotic properties, although a high dose did not lead to
dramatic improvement in cardiac function. Oral epigallocatechin-3-gallate pretreatment may be a novel and
simple cardioprotective method for preventing perioperative cardiac dysfunction in cardiac surgery. (J Thorac
Cardiovasc Surg 2011;141:511-7)E
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SIschemia–reperfusion injury (IRI) remains among the most
serious problems in cardiac surgery. Several mechanisms
and mediators of IRI have been described.1 Reactive oxygen
species reportedly play an important role in the pathogenesis
of myocardial IRI.2,3 Administrations of various free radical
scavengers and exogenous antioxidants have been
demonstrated to reduce myocardial IRI and improve
cardiac function in animal models.4,5
Epigallocatechin-3-gallate (EGCG) is well known to be
the most abundant polyphenolic catechin in green tea. Green
tea is safe, popular, and known for its antioxidant properties,
mainly through scavenging of reactive oxygen species (eg,
superoxide anion, hydrogen peroxide, and hydroxyl radi-
cal).6 Several studies have shown green tea consumption
to have potential protective effects against cardiovascular
disease,7,8 thought to be attributable to its antioxidant
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The Journal of Thoracic and Cative effects of preoperative oral intake of green tea polyphe-
nols against ischemia followed by reperfusion of the heart.
We previously demonstrated, with a Langendorff-perfused
rat heart model, that several exogenous antioxidants may en-
hance recovery after myocardial IRI by diminishing oxidative
stress.10,11 In this study, we evaluated the significance of the
cardioprotective effects against myocardial IRI of oral
pretreatment with a green tea polyphenol and examined its
dose effects, as well as the possible underlying mechanisms,
in an isolated rat heart model.
MATERIALS AND METHODS
Green Tea Polyphenol Solutions
Green tea extract in pure form of EGCG was purchased from DSM Nu-
tritional Products Ltd (Basel, Switzerland). EGCG solutions at concentrations
of 1 mmol/L, 0.1 mmol/L, and 10 mmol/L were made with drinking water.
Animals
Male 11-week-old Sprague–Dawley rats (350–450 g body weight) were
used for this study. All animals in this study received humane care in com-
pliance with the Principles of Laboratory Animal Care formulated by the
National Society for Medical Research and the Guide for the Care and
Use of Laboratory Animals prepared by the Institute of Laboratory Animal
Resources and published by the National Institutes of Health, (www.nap.
edu/catalog/5140.html).
Study Groups
The rats were randomly divided into 4 groups of 12 animals each. In the
0.1-mmol/L, 1-mmol/L, and 10-mmol/L EGCG groups, rats were allowedrdiovascular Surgery c Volume 141, Number 2 511
Abbreviations and Acronyms
8-OHdG ¼ 8-hydroxy-20-deoxyguanosine
dp/dt ¼ first derivative of left ventricular
pressure
EGCG ¼ epigallocatechin-3-gallate
HR ¼ heart rate
IRI ¼ ischemia–reperfusion injury
LV ¼ left ventricle
MAPK ¼ mitogen-activated protein kinase
Evolving Technology/Basic Science Yanagi et al
E
T
/B
Sto drink the respective EGCG solutions as their daily fluid intakes for 2
weeks. In the control group, rats drank regular water for 2 weeks. Fluid
consumption was measured daily for each rat.
Measurement of Plasma EGCG Levels
A technique of liquid chromatography coupled with tandem mass
spectrometry was used to measure EGCG in rat plasma as previously de-
scribed.12 Just before the Langendorff study, a blood sample was obtained
from the inferior vena cava of each rat that had been given EGCG for 2
weeks. Samples were centrifuged at 3000 g for 10 minute. The resulting
plasma (100 mL) was mixed with 20 mL of an internal standard (gallocate-
chin gallate, 0.6 mg/mL) and 20 mL buffer solution (2% ascorbic acid and
1-mol/L sodium acetate, pH 5.0). The mixture was then extracted with
100 mL of a methanol and acetic acid mixture (100/5 volume/volume)
and centrifuged for 15 minutes at 11750g. After centrifugation, 100 mL of
the clear supernatant were transferred to another centrifuge tube, dried under
nitrogen, and reconstituted with 100 mL of mobile phase A. An aliquot of the
solution was directly injected onto the setup for liquid chromatography
coupled with tandem mass spectrometry for analysis, and the plasma
EGCG concentration was calculated.
Heart Isolation and Perfusion
Isolated hearts were perfused with a Langendorff apparatus as previously
described.10 The rats were anesthetized by inhalation of diethyl ether and
intraperitoneal injection of sodium pentobarbital (50 mg/kg). Anticoagula-
tion was achieved with an intravenous injection of heparin (1000 IU/kg).
Each heart was quickly excised, washed in ice-cold saline solution, and
mounted on a nonrecirculating Langendorff apparatus. After cannulation
of the aorta, the coronary circulation was quickly restarted at a constant pres-
sure of 80 mmHg at 37C. Krebs–Henseleit solution (sodium chloride 118
mmol/L, potassium chloride 4.7 mmol/L, magnesium sulfate 1.2 mmol/L,
sodium hydrogen carbonate 25 mmol/L, monobasic potassium phosphate
1.2 mmol/L, calcium chloride 2.5 mmol/L, and glucose 11 mmol/L)
bubbled with a mixture of 95% oxygen and 5% carbon dioxide was used
for perfusion. For measurement of left ventricular (LV) function, a water-
filled latex balloon was inserted through the left atrium into the LV after
a pulmonary arteriotomy. The balloon pressure was adjusted to maintain
LV end-diastolic pressure at 10 mm Hg. After a stabilization period of at
least 20 minutes, the isolated heart was subjected to no-flow global ischemia
at 37C for 30 minutes, followed by 60 minutes of reperfusion. The LV
pressure waveform was traced on a strip chart.Evaluation of LV Function
To measure LV pressure, the latex balloon was connected by a fluid-filled
polyethylene tube to a pressure transducer. After achievement of preischemic
perfusion equilibrium, heart rate (HR), LV developed pressure, and positive
and negative first derivatives of LV pressure (þdp/dt anddp/dt, reflecting
both systolic and diastolic function) were measured and recorded continu-512 The Journal of Thoracic and Cardiovascular Surgously with LV diastolic pressure stabilized at 10 mm Hg. Coronary flow
was measured by collecting coronary effluent buffer. LV function was
assessed by calculating the percentage recovery of each parameter (eg,% re-
covery of HR ¼ HR after 60 minutes of reperfusion/baseline HR3 100%).
Immunohistochemical Assay for Evaluation of
Oxidative Stress
The level of 8-hydroxy-20-deoxyguanosine (8-OHdG), a major product
of oxidative DNA modifications,13 is widely used as a marker of oxidative
stress against DNA.10,14 Cardiac tissues were fixed overnight in
paraformaldehyde phosphate buffer solution immediately after reperfusion
and then dehydrated sequentially with 50% and 70% ethanol for 24
hours. For immunohistochemical analysis, the avidin–biotin complex
method was carried out as previously described.14 Briefly, after deparaffini-
zation of the specimens, appropriately diluted solutions of normal rabbit
serum (Dako Japan Co, Ltd, Kyoto, Japan), mouse monoclonal antibody
against 8-OHdG (Japan Institute for the Control of Aging, Fukuroi, Japan),
biotin-labeled rabbit anti–mouse IgG serum (Dako), and avidin–biotin com-
plex (Vector Laboratories, Inc, Burlingame, Calif) were sequentially applied.
The substrate for alkaline phosphatase (black) was obtained from a vector.
Immunohistologic data (8-OHdG index) were quantified as follows15:
8-OHdG index ¼ S[(X  threshold) 3 area (pixels)]/total cell number,
where X is the staining density indicated in gray scale with ImageJ (National
Institutes of Health, http://rsbweb.nih.gov/ij/) and Photoshop (Adobe
Systems Inc, San Jose, Calif) software.
Western Blotting Analysis for Apoptosis-Related
Proteins
Western blotting was performed to identify apoptosis in the myocardium
at 60 minutes after reperfusion, as previously described.16 Ventricular tissue
samples obtained from ischemic, reperfused hearts (n ¼ 5 per group) were
homogenized on ice in a lysis buffer with protease inhibitor and 1-mmol/L
orthovanadic acid and quantified for protein levels with a commercially
available assay (BCA protein assay reagent kit; Thermo Fisher Scientific
Inc, Rockford, Ill). Proteins (20 mg/sample) were separated with sodium do-
decylsulfate polyacrylamide gels (20%) and electrotransferred onto nitro-
cellulose membranes (Immobilon P; Millipore, Billerica, Mass). After
blocking with 5% nonfat milk in tris(hydroxymethyl)aminomethane-
buffered saline solution containing 0.1% polysorbate 20, membranes
were incubated overnight with the following first antibodies: (1) p38 kinase
(sc-7972) at a 1:1000 dilution, (2) phosphorylated p38 (sc-7973) at a 1:1000
dilution, (3) caspase-3 (C9598) at a 1:1000 dilution, and (4) activated
caspase-3 (C8487) at a 1:1000 dilution. After incubation with these primary
antibodies, horseradish peroxidase–conjugated secondary antibodies were
added (1:4000 dilution) for 1 hour at room temperature. Protein bands
were enhanced with a chemiluminescence Western blotting determination
kit (ECL-Plus; Amersham Pharmacia, Little Chalfont, UK). The band inten-
sity was quantified with imaging software (ImageJ version 1.3).
Statistical Analysis
All data were expressed as mean  SD. Statistical analyses were per-
formed with statistical software (StatView for Windows version 5.0; SAS
Institute Inc, Cary, NC). Data were analyzed by Student t test or 1-factor
analysis of variance. When results were significant by analysis of variance,
differences between individual groups were estimated with the Bonferroni–
Dunn post hoc test.
RESULTS
Plasma EGCG Levels in Rats
In all groups, each rat received on average 30 mL/day of
EGCG solution or tap water. As the dose of EGCG admin-
istered rose, plasma EGCG levels correspondingly increasedery c February 2011
TABLE 1. Baseline parameters before ischemia
Control group
(n ¼ 12)
Epigallocatechin-3-gallate groups
Variable 0.1 mmol/L (n ¼ 12) 1 mmol/L (n ¼ 12) 10 mmol/L (n ¼ 12)
Body weight (g) 422.8  27.9 423.8  19.2 420.1  21.9 428.1  19.1
Heart weight (g) 1.57  0.08 1.61  0.17 1.60  0.14 1.62  0.12
Heart weight/body weight (%) 0.37  0.02 0.37  0.03 0.38  0.03 0.37  0.03
Heart rate (beats/min) 315.4  24.5 312.4  20.4 326.0  32.2 324.5  38.4
LVDP (mm Hg) 96.6  16.4 95.6  11.6 98.5  14.2 98.4  14.3
Maximumþdp/dt (mm Hg/s) 2996.0  538.2 2512.8  301.7 3069.1  727.3 2910.5  654.3
Minimumdp/dt (mm Hg/s) 2569.0  514.8 2243.6  267.7 2526.0  450.0 2370.4  425.6
Coronary flow (mL/min) 14.9  3.8 16.8  3.4 15.1  3.3 17.1  4.8
All values are mean  SD. LVDP, Left ventricular developed pressure; dp/dt, first derivative of left ventricular pressure.
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Sto a greater extent in rats given EGCG solution (0.1, 1, and
10 mmol/L) as drinking fluid for 14 days. Plasma EGCG was
significantly higher in the 10-mmol/L group than in the con-
trol group (92.7  29.8 vs 0 ng/mL, P<.0001), 0.1-mmol/L
group (92.7  29.8 vs 0 ng/mL, P< .0001), and 1-mmol/L
group (92.7  29.8 vs 6.2  2.9 ng/mL, P<.0001). Plasma
EGCG was undetectable in the 0.1-mmol/L group, just as in
the control group.
Baseline Measurement Before Ischemia (Table 1)
There were no significant differences in body or heart
weights before the Langendorff study among the 4 groups.
Moreover, baseline LV function in the Langendorff study
did not differ significantly among the groups.
Cardiac Function After Reperfusion
LV function measurements at 60 minutes after reperfu-
sion are shown in Table 2. The percentage recoveries of
LV developed pressure (Figure 1, B), maximum þdp/dt
(Figure 1, C), and minimum dp/dt (Figure 1, D) after
60 minutes of reperfusion were significantly higher in the
1-mmol/L and 10-mmol/L groups than in the control group.
Among EGCG groups, the percentage recoveries of LV de-
veloped pressure (Figure 1, B), maximumþdp/dt (Figure 1,
C), and minimum dp/dt (Figure 1, D) were significantly
higher in the 1-mmol/L group than in the 0.1-mmol/L and
10-mmol/L groups. There were no significant differences
in HR among the 4 groups (Figure 1, A). Among all cardiac
parameters, recovery after reperfusion in the 0.1-mmol/L
group was almost equal to that in the control group. ThereTABLE 2. Left ventricular function measurements at 60 minutes after rep
Control group
(n ¼ 12)Variable 0.1 mmol/L
Heart rate (beats/min) 311.0  46.1 301.6 
LVDP (mm Hg) 61.0  17.4 59.3 
Maximumþdp/dt (mm Hg/s) 1920.7  591.0 1637.7 
Minimumdp/dt (mm Hg/s) 1589.2  378.9 1403.1 
Coronary flow (mL/min) 10.5  2.7 12.2 
All values are mean  SD. LVDP, Left ventricular developed pressure; dp/dt, first derivati
zP< .05 versus 10 mmol/L. xP< .05 versus control. kP< .05 versus 0.1 mmol/L.
The Journal of Thoracic and Cawere no significant differences in coronary flow at 60 min-
utes of reperfusion among the groups (Table 2).
Oxidative Stress on DNA
Representative myocardial images of 8-OHdG immuno-
histochemical staining are shown in Figure 2, A. In the hearts
of the 1-mmol/L and 10-mmol/L group rats, there were fewer
darkly stained nuclei than in the control and 0.1-mmol/L
groups. As shown in Figure 2, B, the 8-OHdG index calcu-
lated from staining was significantly lower in the 1-mmol/L
group than in the control group (98.2  39.4 vs 244.5 
105.0 3 102, P< .01) and 0.1-mmol/L (98.2  39.4 vs
221.9  79.1 3 102, P< .05) groups. This index was also
significantly lower in the 10-mmol/L group than in the con-
trol group (125.9  83.2 vs 244.5  105.0 3 102, P< .05).
Expression of Apoptosis-Related Proteins
Western blotting analyses for p38 (Figure 3, A) and
caspase-3 (Figure 3, B) showed lower expressions of phos-
phorylated p38 and active caspase-3 in the 1-mmol/L group
than in the control group (P< .05). Phosphorylation of p38
and caspase-3 cleavage were also significantly lower in the
10-mmol/L group than in the control group (P< .05).
DISCUSSION
We found oral pretreatment with EGCG to attenuate myo-
cardial IRI and to preserve LV function after reperfusion in
a Langendorff-perfused rat heart model. The antioxidative
and antiapoptotic properties of EGCG may be involved in
this cardioprotective effect. In addition, oral intake oferfusion
Epigallocatechin-3-gallate groups
(n ¼ 12) 1 mmol/L (n ¼ 12) 10 mmol/L (n ¼ 12)
26.1 309.9  22.3 298.4  28.3
7.9 83.9  12.8*yz 72.3  10.2xk
174.8 2648.6  599.5*z 2262.0  595.4k
167.1 2033.1  291.7*yz 1745.0  345.9k
1.9 13.0  2.4 12.7  3.3
ve of left ventricular pressure. *P< .01 versus control. yP< .01 versus 0.1 mmol/L.
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FIGURE 1. Recovery of left ventricular function at 60 minutes of reperfusion as percentage before ischemia. A, Heart rate (HR) did not differ significantly
among groups. B–D, Recoveries of left ventricular developed pressure (LVDP, B), maximum positive first derivative of left ventricular pressure (Maxþdp/dt,
C), and minimum negative first derivative of left ventricular pressure (Mindp/dt, D) in 1-mmol/L and 10-mmol/L groups were higher than in control and
0.1-mmol/L groups. Recoveries of left ventricular developed pressure and maximum positive and minimum negative first derivatives of left ventricular pres-
sure were higher in 1-mmol/L group than in 10-mmol/L group. All values shown as mean  SD, n ¼ 12 per group.
Evolving Technology/Basic Science Yanagi et al
E
T
/B
Sa high dose of EGCG did not dramatically improve cardiac
function after ischemia–reperfusion.
EGCG and Antioxidative Capacity
This novel pretreatment with EGCG, putting the whole
body into an antioxidation state before IRI, may serve as
a quite reasonable preconditioning method. One of the major
theories, supported by most experimental evidence, suggests
that reactive oxygen species generation is responsible for
postischemic contractile dysfunction.17 Furthermore, clini-
cal studies have shown that reactive oxygen species genera-
tion starts before cardiac surgery and that the availabilities of
protective antioxidants depend on preoperative plasma anti-
oxidant status.18 In this experiment, oral pretreatment with
EGCG for 2 weeks before the Langendorff study had no
effects on the animals’ baseline cardiac parameters. Under
IRI conditions, however, LV function was better maintained
in the group pretreated with 1 mmol/L EGCG. The potent514 The Journal of Thoracic and Cardiovascular Surgantioxidative capacity of green tea polyphenols could
contribute to LV function recovery after reperfusion, as
shown by the lower 8-OHdG indices in the 1-mmol/L and
10-mmol/L groups.
EGCG and Antiapoptotic Effects
Another mechanism possibly underlying the cardiopro-
tective effects of EGCG is its antiapoptotic effect, exerted
through oral pretreatment, which may be associated with
the preservation of LV function. Oxidative stress is now
considered to be a major contributor, serving as a trigger,
to myocardial apoptosis. Oxidative stress–induced apoptosis
and its prevention by antioxidants have therefore also been
analyzed.19 With respect to catechins, several in vitro inves-
tigations have shown EGCG to modulate multiple signal
transduction pathways of apoptosis, such as mitogen-
activated protein kinases (MAPKs). Furthermore, several
studies have found caspase-3 cleavage, a downstreamery c February 2011
FIGURE 2. Oxidative stress on DNA in cardiomyocytes. A, Representa-
tive immunohistochemical analysis images for 8-hydroxy-20-deoxyguano-
sine (8-OHdG) were obtained with specific monoclonal antibody. Stained
nuclei are indicated by arrows. Bar represents 50 mm. B, Quantification
of oxidative stress on DNA, as indicated by 8-hydroxy-20-deoxyguanosine
index. All values shown as mean  SD.
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ulating apoptosis, to be blocked by EGCG. In particular,
EGCG has been shown to reduce the levels of p38 MAPK
phosphorylation,20 and several studies have confirmed inhi-
bition of p38 MAPK phosphorylation to decrease apoptosis
and improve cardiac function after myocardial IRI.21
Consistent with these findings, our Western blotting analysis
demonstrated EGCG to protect against myocardial apoptosis
by blocking p38 MAPK phosphorylation and caspase-3
cleavage, indicating that oral pretreatment with EGCG
preserved LV function possibly by inhibiting myocardial
apoptosis.
Dose Effects of EGCG
In this study, oral pretreatment with a high dose of EGCG
did not yield the most potent cardioprotective effects. The
cardiac function recovery rates after reperfusion were actu-
ally lower in the 10-mmol/L group than in the 1-mmol/L
group, despite the blood EGCG concentration remainingThe Journal of Thoracic and Cahigher in the 10-mmol/L group. The plasma EGCG levels
of rats given 1-mmol/L EGCG for 2 weeks may have ex-
ceeded the saturation point for cardioprotective effects.
This result may also, however, be related to some additional
adverse effects of EGCG. One possible adverse effect is that
EGCG at high concentrations produces an excess of nitric
oxide through activation of endothelial nitric oxide synthase.
If nitric oxide exceeds a certain level, it reacts with superox-
ide anion under postischemic reperfusion conditions and
yields more toxic radicals, such as hydroxyl radical and
peroxynitrite anion, as demonstrated in several studies.22
The toxic activity of these reaction products may exceed
the scavenger activity of EGCG, possibly leading to the sup-
pression of heart function. These results underscore the im-
portance of establishing the optimal oral EGCG dose to
maintain recovery of cardiac function and minimize surgical
complications, in anticipation of clinical application of
EGCG.
Optimal Delivery of EGCG
We advocate that EGCG should be administered orally as
a preoperative measure. Recently, with respect to the safety
of EGCG, excessively high concentrations have been shown
to be cytotoxic and to trigger genotoxic events in mamma-
lian cells.23 Direct administration of EGCG to the myocar-
dium, such as by intravenous or intracoronary injection,
reportedly produces harmful side effects, particularly at
high doses. Oral EGCG, however, even when given as
a very high bolus dose, is safe in human beings, as shown
by clinical trial.24 In this study, we selected the 2-week
oral protocol for administration of EGCG on the basis of
a report on the bioavailability of green tea polyphenols in ro-
dents during long-term green tea consumption in drinking
fluid.25 Plasma concentrations of EGCG were shown to
gradually increase in the first 2 weeks and then reach a pla-
teau in rats given EGCG in drinking fluid.25 In considering
clinical applications, we will need to establish a period of
oral administration of EGCG before heart surgery, referring
to several clinical studies to determine the safety and phar-
macokinetics of green tea polyphenols with long-term oral
administration of EGCG.24
Study Limitations
This study has several limitations. First, the heart model
used in our experiment may not fully reflect in vivo condi-
tions because of the lack of blood components such as neu-
trophils, platelets, and blood-derived cytokines. Several
studies have demonstrated that neutrophils play an important
role in the pathogenesis of IRI. An in vivo study taking into
account the influence of blood is therefore in progress. Sec-
ond, the type of ischemia used in this experimental model
was global no-flow ischemia without cardioplegia, which
is unlike the type of ischemia used in human heart surgery.
This type of ischemia was adopted for this model to facilitaterdiovascular Surgery c Volume 141, Number 2 515
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eliminating other cardioprotective factors as far as possible.
In the future, further investigations are needed to clarify the
cardioprotective effects of oral pretreatment with EGCG in
a larger animal model of ischemia with cardioplegia and
cardiopulmonary bypass, in view of its clinical application
to human heart surgery. These issues will be addressed in fu-
ture green tea polyphenol clinical trials. Third, in this study,
we did not incorporate preischemic measurement of oxida-
tive stress or apoptosis. Although the baseline cardiac func-
tion did not differ among the groups, we cannot rule out the
possibility that preischemic oxidative stress and apoptosis
were suppressed in the EGCG groups. This point needs fur-
ther investigation. Fourth, the involvement of p38 MAPK
expression in apoptosis is still controversial. We cannot def-
initely conclude that the cardioprotective effect of EGCG
exhibited in this study is attributable to p38-mediated apo-
ptosis suppression. We selected p38 for evaluation in this
study because in several previous reports EGCG was shown
to suppress apoptosis through inhibition of p38 activation
under conditions of myocardial IRI.20CONCLUSIONS
Oral pretreatment with EGCG, a green tea polyphenol, at-
tenuated myocardial IRI and enhanced cardiac function re-
covery after ischemia followed by reperfusion in an
isolated rat heart model. The mechanisms of oxidative stress
suppression and myocardial apoptosis suppression may be
involved in the cardioprotective effects of EGCG. In addi-
tion, oral intake of a high dose of EGCG did not dramatically
improve cardiac function after ischemia–reperfusion. EGCG
pretreatment by oral intake could be a novel and simple pre-516 The Journal of Thoracic and Cardiovascular Surgconditioning cardioprotective method for preventing perio-
perative cardiac dysfunction in cardiac surgical patients.
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